Concepts (374)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anopheles | 82 | 2024 | 309 | 14.550 |
Why?
|
| Malaria | 49 | 2024 | 213 | 6.960 |
Why?
|
| Insecticides | 31 | 2022 | 135 | 6.130 |
Why?
|
| Insecticide Resistance | 35 | 2022 | 131 | 6.030 |
Why?
|
| Insect Vectors | 30 | 2016 | 99 | 5.000 |
Why?
|
| Animals | 94 | 2024 | 1081 | 4.620 |
Why?
|
| Mosquito Vectors | 19 | 2024 | 111 | 3.600 |
Why?
|
| Pyrethrins | 19 | 2022 | 72 | 2.830 |
Why?
|
| Mosquito Control | 24 | 2022 | 98 | 2.710 |
Why?
|
| Plasmodium falciparum | 9 | 2019 | 64 | 1.380 |
Why?
|
| Disease Vectors | 7 | 2014 | 17 | 1.270 |
Why?
|
| Genetic Variation | 5 | 2020 | 175 | 1.210 |
Why?
|
| Genetics, Population | 6 | 2020 | 52 | 1.180 |
Why?
|
| Diptera | 2 | 2020 | 2 | 1.160 |
Why?
|
| Africa | 16 | 2020 | 376 | 1.090 |
Why?
|
| Malaria, Falciparum | 6 | 2019 | 39 | 1.070 |
Why?
|
| Insect Proteins | 5 | 2020 | 14 | 1.040 |
Why?
|
| DDT | 9 | 2022 | 30 | 1.020 |
Why?
|
| Temperature | 7 | 2020 | 56 | 1.020 |
Why?
|
| Beauveria | 5 | 2014 | 13 | 0.990 |
Why?
|
| Female | 51 | 2022 | 9103 | 0.950 |
Why?
|
| Insect Bites and Stings | 5 | 2019 | 9 | 0.950 |
Why?
|
| Culicidae | 2 | 2020 | 11 | 0.810 |
Why?
|
| Humans | 51 | 2022 | 14537 | 0.790 |
Why?
|
| Polymerase Chain Reaction | 12 | 2018 | 260 | 0.730 |
Why?
|
| Permethrin | 7 | 2022 | 29 | 0.720 |
Why?
|
| Postmortem Changes | 1 | 2020 | 1 | 0.710 |
Why?
|
| Monte Carlo Method | 1 | 2020 | 11 | 0.710 |
Why?
|
| Biodiversity | 1 | 2020 | 11 | 0.690 |
Why?
|
| Nitriles | 5 | 2017 | 27 | 0.680 |
Why?
|
| Communicable Disease Control | 2 | 2018 | 101 | 0.670 |
Why?
|
| Male | 33 | 2019 | 6754 | 0.590 |
Why?
|
| Spider Bites | 1 | 2017 | 1 | 0.570 |
Why?
|
| Blister | 1 | 2017 | 1 | 0.570 |
Why?
|
| Thumb | 1 | 2017 | 1 | 0.570 |
Why?
|
| DNA, Mitochondrial | 5 | 2020 | 31 | 0.570 |
Why?
|
| Pain | 1 | 2017 | 41 | 0.560 |
Why?
|
| Organothiophosphorus Compounds | 1 | 2015 | 2 | 0.520 |
Why?
|
| Mutation | 5 | 2020 | 306 | 0.500 |
Why?
|
| Geography | 9 | 2020 | 60 | 0.500 |
Why?
|
| Feeding Behavior | 5 | 2020 | 60 | 0.500 |
Why?
|
| Mining | 1 | 2015 | 41 | 0.500 |
Why?
|
| Tanzania | 10 | 2020 | 88 | 0.490 |
Why?
|
| Species Specificity | 10 | 2019 | 49 | 0.470 |
Why?
|
| Mali | 3 | 2021 | 20 | 0.460 |
Why?
|
| Parasitic Diseases | 1 | 2014 | 2 | 0.460 |
Why?
|
| Spores, Fungal | 3 | 2012 | 8 | 0.460 |
Why?
|
| Plasmodium berghei | 1 | 2013 | 1 | 0.430 |
Why?
|
| Plasmodium | 4 | 2018 | 14 | 0.430 |
Why?
|
| Chromosome Inversion | 3 | 2003 | 9 | 0.430 |
Why?
|
| Cimicidae | 1 | 2013 | 1 | 0.420 |
Why?
|
| South Africa | 25 | 2024 | 7596 | 0.400 |
Why?
|
| Insecticide-Treated Bednets | 4 | 2016 | 8 | 0.400 |
Why?
|
| Biological Assay | 4 | 2017 | 32 | 0.390 |
Why?
|
| Adult | 14 | 2021 | 5913 | 0.390 |
Why?
|
| Culex | 2 | 2019 | 6 | 0.380 |
Why?
|
| Insect Control | 1 | 2011 | 10 | 0.370 |
Why?
|
| Housing | 4 | 2018 | 24 | 0.360 |
Why?
|
| Specialty Boards | 1 | 2010 | 1 | 0.360 |
Why?
|
| Pathology | 1 | 2010 | 2 | 0.360 |
Why?
|
| Internship and Residency | 1 | 2010 | 6 | 0.360 |
Why?
|
| Hematology | 1 | 2010 | 4 | 0.360 |
Why?
|
| Zambia | 7 | 2022 | 115 | 0.350 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2009 | 25 | 0.350 |
Why?
|
| Larva | 5 | 2018 | 42 | 0.340 |
Why?
|
| Chromosome Mapping | 4 | 2009 | 20 | 0.320 |
Why?
|
| Animal Distribution | 3 | 2024 | 12 | 0.320 |
Why?
|
| Polymorphism, Restriction Fragment Length | 5 | 2018 | 22 | 0.310 |
Why?
|
| DNA | 6 | 2022 | 73 | 0.310 |
Why?
|
| Sodium Channels | 1 | 2008 | 6 | 0.300 |
Why?
|
| Carbamates | 1 | 2008 | 12 | 0.300 |
Why?
|
| Demography | 2 | 2012 | 105 | 0.290 |
Why?
|
| Spatio-Temporal Analysis | 2 | 2019 | 14 | 0.280 |
Why?
|
| Microsatellite Repeats | 4 | 2020 | 14 | 0.280 |
Why?
|
| Adolescent | 9 | 2019 | 2985 | 0.280 |
Why?
|
| Models, Biological | 2 | 2019 | 77 | 0.270 |
Why?
|
| Genes, Insect | 2 | 2005 | 8 | 0.270 |
Why?
|
| Zimbabwe | 4 | 2022 | 120 | 0.270 |
Why?
|
| Kenya | 5 | 2016 | 183 | 0.270 |
Why?
|
| Middle Aged | 9 | 2019 | 3601 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 4 | 2011 | 181 | 0.250 |
Why?
|
| Molecular Sequence Data | 9 | 2013 | 263 | 0.250 |
Why?
|
| Young Adult | 7 | 2018 | 2498 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 150 | 0.250 |
Why?
|
| Pest Control, Biological | 3 | 2012 | 7 | 0.250 |
Why?
|
| Africa, Southern | 4 | 2020 | 91 | 0.250 |
Why?
|
| Ovum | 2 | 2016 | 2 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 262 | 0.250 |
Why?
|
| Base Sequence | 7 | 2009 | 149 | 0.240 |
Why?
|
| Anemia | 3 | 2019 | 41 | 0.240 |
Why?
|
| Survival Analysis | 7 | 2014 | 149 | 0.240 |
Why?
|
| Seasons | 6 | 2024 | 154 | 0.220 |
Why?
|
| Phylogeny | 4 | 2018 | 231 | 0.210 |
Why?
|
| Child, Preschool | 6 | 2019 | 1748 | 0.210 |
Why?
|
| Phenylcarbamates | 4 | 2013 | 8 | 0.210 |
Why?
|
| Child | 7 | 2022 | 2242 | 0.210 |
Why?
|
| Parasites | 1 | 2022 | 6 | 0.210 |
Why?
|
| Bayes Theorem | 2 | 2020 | 81 | 0.200 |
Why?
|
| Biology | 1 | 2022 | 1 | 0.200 |
Why?
|
| Entomology | 2 | 2013 | 4 | 0.200 |
Why?
|
| Ghana | 3 | 2011 | 67 | 0.190 |
Why?
|
| Cote d'Ivoire | 1 | 2021 | 6 | 0.190 |
Why?
|
| Namibia | 3 | 2018 | 19 | 0.190 |
Why?
|
| Environment | 2 | 2020 | 22 | 0.190 |
Why?
|
| Gene Frequency | 2 | 2002 | 122 | 0.180 |
Why?
|
| Cadaver | 1 | 2020 | 5 | 0.180 |
Why?
|
| Hemoglobinometry | 1 | 2000 | 1 | 0.180 |
Why?
|
| Reagent Strips | 1 | 2000 | 2 | 0.180 |
Why?
|
| Islands | 1 | 2020 | 2 | 0.170 |
Why?
|
| Tropical Climate | 1 | 2020 | 4 | 0.170 |
Why?
|
| Time Factors | 4 | 2014 | 507 | 0.170 |
Why?
|
| Blood | 3 | 2011 | 51 | 0.170 |
Why?
|
| Disease Management | 2 | 2017 | 74 | 0.170 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2019 | 2 | 0.170 |
Why?
|
| Uganda | 1 | 2020 | 197 | 0.160 |
Why?
|
| Behavior | 1 | 2019 | 5 | 0.160 |
Why?
|
| Human Migration | 1 | 2019 | 8 | 0.160 |
Why?
|
| Standard of Care | 1 | 2019 | 30 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 253 | 0.160 |
Why?
|
| Mozambique | 4 | 2013 | 55 | 0.160 |
Why?
|
| Genome, Mitochondrial | 1 | 2018 | 1 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 1998 | 4 | 0.150 |
Why?
|
| Genotype | 5 | 2013 | 442 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1998 | 17 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 39 | 0.150 |
Why?
|
| Guinea | 1 | 2018 | 6 | 0.150 |
Why?
|
| Insemination | 1 | 2018 | 3 | 0.150 |
Why?
|
| Behavior, Animal | 1 | 2018 | 6 | 0.150 |
Why?
|
| Disease Outbreaks | 2 | 2009 | 111 | 0.150 |
Why?
|
| Botswana | 1 | 2018 | 24 | 0.150 |
Why?
|
| Malawi | 5 | 2022 | 87 | 0.150 |
Why?
|
| Pesticide Synergists | 2 | 2014 | 9 | 0.140 |
Why?
|
| Gene Duplication | 2 | 2009 | 13 | 0.140 |
Why?
|
| Spiders | 1 | 2017 | 1 | 0.140 |
Why?
|
| Sudan | 2 | 2014 | 9 | 0.140 |
Why?
|
| Analgesics | 1 | 2017 | 4 | 0.140 |
Why?
|
| Symptom Assessment | 1 | 2017 | 16 | 0.140 |
Why?
|
| Africa, Central | 3 | 2022 | 7 | 0.140 |
Why?
|
| Benchmarking | 1 | 2017 | 10 | 0.140 |
Why?
|
| DNA Primers | 6 | 2010 | 55 | 0.140 |
Why?
|
| Stomatitis | 1 | 1997 | 2 | 0.140 |
Why?
|
| Congo | 3 | 2011 | 9 | 0.140 |
Why?
|
| Incidence | 2 | 2017 | 685 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2010 | 133 | 0.140 |
Why?
|
| Population Surveillance | 2 | 2009 | 325 | 0.140 |
Why?
|
| Aedes | 1 | 2016 | 7 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2017 | 889 | 0.140 |
Why?
|
| Drug Resistance | 3 | 2011 | 35 | 0.140 |
Why?
|
| HLA Antigens | 1 | 1997 | 50 | 0.130 |
Why?
|
| Piper nigrum | 1 | 2016 | 2 | 0.130 |
Why?
|
| Benzodioxoles | 1 | 2016 | 2 | 0.130 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2016 | 2 | 0.130 |
Why?
|
| Alkaloids | 1 | 2016 | 3 | 0.130 |
Why?
|
| Piperidines | 1 | 2016 | 4 | 0.130 |
Why?
|
| Cattle | 3 | 2020 | 28 | 0.130 |
Why?
|
| Pheromones | 1 | 2016 | 5 | 0.130 |
Why?
|
| Reticulocytes | 1 | 2015 | 5 | 0.130 |
Why?
|
| Iron | 1 | 2015 | 32 | 0.130 |
Why?
|
| Hemoglobins | 1 | 2015 | 40 | 0.120 |
Why?
|
| Insect Repellents | 1 | 2015 | 2 | 0.120 |
Why?
|
| Africa South of the Sahara | 2 | 2016 | 353 | 0.120 |
Why?
|
| Hemophilia A | 2 | 2012 | 106 | 0.120 |
Why?
|
| Human Body | 1 | 2015 | 4 | 0.120 |
Why?
|
| Dehydration | 1 | 2014 | 1 | 0.120 |
Why?
|
| Water Loss, Insensible | 1 | 2014 | 1 | 0.120 |
Why?
|
| Acclimatization | 1 | 2014 | 2 | 0.120 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 13 | 0.120 |
Why?
|
| Hematologic Tests | 1 | 1994 | 11 | 0.120 |
Why?
|
| Cluster Analysis | 4 | 2017 | 65 | 0.120 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 2014 | 1 | 0.120 |
Why?
|
| Birds | 1 | 2014 | 2 | 0.120 |
Why?
|
| Residence Characteristics | 2 | 2007 | 57 | 0.120 |
Why?
|
| Biomarkers | 1 | 2015 | 327 | 0.110 |
Why?
|
| Environmental Pollutants | 1 | 2014 | 16 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 41 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 127 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 1422 | 0.110 |
Why?
|
| Nutritional Status | 1 | 1994 | 76 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2009 | 198 | 0.110 |
Why?
|
| Oocytes | 1 | 2013 | 2 | 0.110 |
Why?
|
| Cell Count | 1 | 2013 | 10 | 0.110 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 38 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2013 | 11 | 0.100 |
Why?
|
| Mice | 1 | 2013 | 135 | 0.100 |
Why?
|
| Pupa | 1 | 2013 | 12 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 40 | 0.100 |
Why?
|
| Microbial Viability | 1 | 2012 | 11 | 0.100 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1992 | 5 | 0.100 |
Why?
|
| Coagulants | 1 | 2012 | 10 | 0.100 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1992 | 7 | 0.100 |
Why?
|
| Phylogeography | 1 | 2012 | 15 | 0.100 |
Why?
|
| Factor VIIa | 1 | 2012 | 14 | 0.100 |
Why?
|
| Haplotypes | 1 | 2012 | 125 | 0.100 |
Why?
|
| Hemophilia B | 1 | 2012 | 23 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 73 | 0.100 |
Why?
|
| Aged | 5 | 2018 | 1740 | 0.100 |
Why?
|
| Microarray Analysis | 1 | 2011 | 3 | 0.090 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2010 | 5 | 0.090 |
Why?
|
| Quantitative Trait Loci | 2 | 2009 | 7 | 0.090 |
Why?
|
| Phenotype | 3 | 2019 | 158 | 0.090 |
Why?
|
| Genitalia, Male | 2 | 2018 | 9 | 0.090 |
Why?
|
| Sporozoites | 2 | 2017 | 9 | 0.090 |
Why?
|
| Curriculum | 1 | 2010 | 27 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 90 | 0.090 |
Why?
|
| Fenitrothion | 1 | 2009 | 1 | 0.090 |
Why?
|
| Taq Polymerase | 1 | 2009 | 3 | 0.090 |
Why?
|
| Rural Population | 4 | 2018 | 654 | 0.080 |
Why?
|
| Space-Time Clustering | 1 | 2009 | 6 | 0.080 |
Why?
|
| Prevalence | 4 | 2017 | 1192 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 176 | 0.080 |
Why?
|
| Metarhizium | 1 | 2008 | 1 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2024 | 799 | 0.080 |
Why?
|
| Water Supply | 1 | 2008 | 10 | 0.080 |
Why?
|
| Reproduction | 2 | 2011 | 25 | 0.080 |
Why?
|
| World Health Organization | 2 | 2017 | 137 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2008 | 55 | 0.070 |
Why?
|
| Tuberculosis, Bovine | 1 | 2007 | 1 | 0.070 |
Why?
|
| Mycobacterium bovis | 1 | 2007 | 4 | 0.070 |
Why?
|
| Goats | 1 | 2007 | 3 | 0.070 |
Why?
|
| Sheep | 1 | 2007 | 9 | 0.070 |
Why?
|
| Propoxur | 1 | 2007 | 9 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2007 | 17 | 0.070 |
Why?
|
| Parasitemia | 1 | 2007 | 3 | 0.070 |
Why?
|
| Environmental Monitoring | 1 | 2007 | 20 | 0.070 |
Why?
|
| Animals, Genetically Modified | 2 | 2007 | 2 | 0.070 |
Why?
|
| Chromosomes | 2 | 2009 | 3 | 0.070 |
Why?
|
| Ductus Arteriosus | 1 | 1986 | 1 | 0.070 |
Why?
|
| Population Dynamics | 2 | 2019 | 27 | 0.070 |
Why?
|
| Fetal Death | 1 | 1986 | 6 | 0.070 |
Why?
|
| Africa, Eastern | 1 | 2006 | 17 | 0.070 |
Why?
|
| Indomethacin | 1 | 1986 | 17 | 0.070 |
Why?
|
| Epidemiological Monitoring | 1 | 2007 | 45 | 0.070 |
Why?
|
| Multigene Family | 1 | 2005 | 6 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2005 | 17 | 0.060 |
Why?
|
| Introns | 1 | 2005 | 13 | 0.060 |
Why?
|
| Exons | 1 | 2005 | 17 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 27 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2004 | 99 | 0.060 |
Why?
|
| Physical Chromosome Mapping | 1 | 2005 | 1 | 0.060 |
Why?
|
| Evolution, Molecular | 1 | 2005 | 60 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 139 | 0.060 |
Why?
|
| Ferritins | 2 | 2015 | 23 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 48 | 0.060 |
Why?
|
| Age Factors | 2 | 2017 | 370 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 385 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 2 | 2002 | 25 | 0.060 |
Why?
|
| Sequence Alignment | 3 | 2009 | 59 | 0.060 |
Why?
|
| Karyotyping | 1 | 2003 | 4 | 0.060 |
Why?
|
| Plasmodium malariae | 1 | 2003 | 2 | 0.050 |
Why?
|
| Humidity | 2 | 2014 | 5 | 0.050 |
Why?
|
| Wolbachia | 1 | 2003 | 1 | 0.050 |
Why?
|
| California | 1 | 2003 | 9 | 0.050 |
Why?
|
| Sex Ratio | 1 | 2003 | 3 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2003 | 18 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2002 | 7 | 0.050 |
Why?
|
| Sex Factors | 2 | 2014 | 227 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 42 | 0.050 |
Why?
|
| DNA, Ribosomal Spacer | 2 | 2017 | 9 | 0.050 |
Why?
|
| Infant | 2 | 2019 | 2244 | 0.050 |
Why?
|
| Risk Factors | 3 | 2017 | 1475 | 0.050 |
Why?
|
| Prothrombin Time | 3 | 2012 | 15 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 468 | 0.040 |
Why?
|
| Medical Audit | 1 | 2000 | 26 | 0.040 |
Why?
|
| Warfarin | 1 | 2000 | 19 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2009 | 563 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2000 | 57 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2000 | 125 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 5 | 0.040 |
Why?
|
| Genetic Carrier Screening | 1 | 1999 | 12 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 9 | 0.040 |
Why?
|
| Developed Countries | 1 | 2019 | 24 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 32 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 34 | 0.040 |
Why?
|
| Social Behavior | 1 | 2019 | 5 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 2019 | 115 | 0.040 |
Why?
|
| Disease Notification | 2 | 2009 | 14 | 0.040 |
Why?
|
| Crosses, Genetic | 2 | 2010 | 4 | 0.040 |
Why?
|
| Urbanization | 1 | 1998 | 11 | 0.040 |
Why?
|
| Patient Transfer | 1 | 1998 | 6 | 0.040 |
Why?
|
| Hemostasis | 1 | 1998 | 15 | 0.040 |
Why?
|
| Alleles | 2 | 2004 | 143 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 42 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 1998 | 57 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 8 | 0.040 |
Why?
|
| Democratic Republic of the Congo | 1 | 2017 | 10 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2018 | 17 | 0.040 |
Why?
|
| Agricultural Irrigation | 1 | 2017 | 1 | 0.040 |
Why?
|
| Oryza | 1 | 2017 | 3 | 0.040 |
Why?
|
| Gene Expression | 1 | 2017 | 43 | 0.040 |
Why?
|
| RNA, Protozoan | 1 | 2017 | 5 | 0.040 |
Why?
|
| Perception | 1 | 2017 | 42 | 0.040 |
Why?
|
| Lidocaine | 1 | 1997 | 1 | 0.030 |
Why?
|
| Sucralfate | 1 | 1997 | 1 | 0.030 |
Why?
|
| Radiotherapy | 1 | 1997 | 3 | 0.030 |
Why?
|
| Betamethasone | 1 | 1997 | 3 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1997 | 6 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 2 | 2012 | 13 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1997 | 17 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 435 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 1997 | 6 | 0.030 |
Why?
|
| Senegal | 1 | 2016 | 3 | 0.030 |
Why?
|
| Aging | 1 | 2017 | 109 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 72 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2017 | 109 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 1997 | 62 | 0.030 |
Why?
|
| Developing Countries | 1 | 2019 | 400 | 0.030 |
Why?
|
| Odorants | 1 | 2016 | 2 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 279 | 0.030 |
Why?
|
| Pregnancy | 2 | 2015 | 1862 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2015 | 15 | 0.030 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2015 | 9 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2015 | 21 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2015 | 2 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1998 | 280 | 0.030 |
Why?
|
| Cameroon | 2 | 2007 | 9 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 12 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 76 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 96 | 0.030 |
Why?
|
| Hemoglobin SC Disease | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sickle Cell Trait | 1 | 2014 | 3 | 0.030 |
Why?
|
| Pain Management | 1 | 2014 | 12 | 0.030 |
Why?
|
| Eosinophilia | 1 | 1994 | 2 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 1994 | 4 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1994 | 11 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1994 | 24 | 0.030 |
Why?
|
| Folic Acid | 1 | 1994 | 12 | 0.030 |
Why?
|
| Zygote | 1 | 2013 | 2 | 0.030 |
Why?
|
| Drug Storage | 1 | 2012 | 2 | 0.030 |
Why?
|
| Desiccation | 1 | 2012 | 15 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2017 | 1479 | 0.030 |
Why?
|
| Thrombin | 1 | 2012 | 8 | 0.030 |
Why?
|
| Electrophoresis | 1 | 1992 | 3 | 0.030 |
Why?
|
| Half-Life | 1 | 2012 | 22 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 44 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 56 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 125 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 7 | 0.020 |
Why?
|
| Drug Stability | 1 | 2011 | 13 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 55 | 0.020 |
Why?
|
| Sexual Behavior, Animal | 1 | 2011 | 13 | 0.020 |
Why?
|
| Animal Feed | 1 | 2011 | 3 | 0.020 |
Why?
|
| Carbohydrates | 1 | 2011 | 5 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 272 | 0.020 |
Why?
|
| Life Cycle Stages | 1 | 2011 | 16 | 0.020 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 2010 | 2 | 0.020 |
Why?
|
| Global Health | 1 | 2012 | 193 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2010 | 7 | 0.020 |
Why?
|
| Classification | 1 | 2009 | 2 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2009 | 9 | 0.020 |
Why?
|
| Fluorescence | 1 | 2009 | 9 | 0.020 |
Why?
|
| Hybridization, Genetic | 1 | 2009 | 3 | 0.020 |
Why?
|
| DNA, Intergenic | 1 | 2009 | 3 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 303 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 171 | 0.020 |
Why?
|
| Software | 1 | 2009 | 37 | 0.020 |
Why?
|
| Inactivation, Metabolic | 1 | 2008 | 3 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2009 | 80 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 480 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 411 | 0.020 |
Why?
|
| Rain | 1 | 2007 | 2 | 0.020 |
Why?
|
| Acetylcholinesterase | 1 | 2007 | 12 | 0.020 |
Why?
|
| Obstetric Labor, Premature | 1 | 1986 | 6 | 0.020 |
Why?
|
| Edema | 1 | 1986 | 7 | 0.020 |
Why?
|
| Transformation, Genetic | 1 | 2002 | 4 | 0.010 |
Why?
|
| Ecology | 1 | 2002 | 5 | 0.010 |
Why?
|
| Public Opinion | 1 | 2002 | 6 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 112 | 0.010 |
Why?
|
| Public Health | 1 | 2002 | 124 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 43 | 0.010 |
Why?
|
| Thrombin Time | 1 | 1998 | 2 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1998 | 10 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 1998 | 16 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 1998 | 237 | 0.010 |
Why?
|